Federal Hemp THC Limits: Legal Framework and Industry Impact

Executive Summary

Federal hemp THC limits—currently set at 0.3% delta-9 THC by dry weight under the 2018 Farm Bill—remain the most contentious regulatory boundary in American cannabis policy. This arbitrary threshold, adopted from a 1976 Canadian research paper, determines whether a cannabis plant is federally legal hemp or Schedule I marijuana, creating a binary classification that governs billions in commerce, thousands of farming operations, and the legal status of millions of consumers. The 0.3% limit has spawned a $28 billion intoxicating hemp market exploiting loopholes through delta-8 THC, THCA flower, and other semi-synthetic cannabinoids, while simultaneously criminalizing farmers whose compliant crops test "hot" at 0.31% due to environmental factors. As of June 2026, the debate over raising, eliminating, or restructuring this limit involves the DEA, FDA, USDA, state agriculture departments, multi-state operators, hemp farmers, tribal nations, and consumer safety advocates—each with competing economic and public health stakes in a regulatory framework that industry experts increasingly describe as scientifically indefensible and commercially unworkable.

Why This Matters

The federal hemp THC limit affects 7,200 licensed hemp farms across 43 states, a $28 billion intoxicating hemp market, and the legal status of products sold in 65,000+ retail locations nationwide. For farmers, the 0.3% threshold represents an existential compliance risk: crops testing above the limit must be destroyed, costing individual operations $50,000 to $300,000 per failed harvest according to USDA data. A 2025 National Hemp Association survey found 18% of outdoor hemp farmers experienced at least one "hot" crop in the previous two years, with total industry losses exceeding $140 million annually. For consumers, the limit creates legal confusion and safety gaps. Products marketed as "legal hemp" containing delta-8 THC, delta-10 THC, THC-O, and THCA flower—all derived from compliant hemp but producing intoxicating effects—occupy retail shelves in states without adult-use marijuana programs. The FDA has received 2,847 adverse event reports related to delta-8 products since 2021, including 127 hospitalizations, yet lacks clear authority to regulate these substances under current hemp definitions. Multi-state cannabis operators view the hemp loophole as a $4.2 billion annual revenue threat, according to a 2025 Viridian Capital Advisors analysis. Licensed marijuana retailers in California, Colorado, and Michigan report 15-30% revenue declines in markets where intoxicating hemp products face no testing requirements, no purchase limits, and no age verification beyond retailer discretion. The economic tension has created an unusual alliance between cannabis industry groups and law enforcement organizations, both advocating for stricter hemp THC controls—though for divergent reasons. State governments face fiscal implications: 23 states have enacted their own hemp THC limits ranging from 0.3% to 1.0% total THC, creating a patchwork that complicates interstate commerce and enforcement. Agricultural departments in Kentucky, North Carolina, and Tennessee—states with significant hemp acreage—have requested federal flexibility to adopt "total THC" testing methodologies that account for THCA conversion, a change that would reduce crop destruction rates by an estimated 40%.

Background and History

The 1976 Origin: Ernest Small's Taxonomic Compromise

The 0.3% delta-9 THC threshold originated not from pharmacological research but from a 1976 taxonomic study by Canadian plant scientist Ernest Small. In his monograph "The Species Problem in Cannabis," Small proposed 0.3% as an arbitrary dividing line to distinguish fiber/seed cultivars from drug cultivars for botanical classification purposes. Small himself noted the limit was "not based on any qualitative or quantitative assessment of the intoxicating properties" but rather represented a practical midpoint in the bimodal distribution of THC content he observed in cannabis populations. The distinction was taxonomic convenience, not toxicological science. For two decades, this academic threshold remained obscure outside botanical circles. Cannabis remained federally prohibited under the Controlled Substances Act of 1970, which classified all Cannabis sativa L. as Schedule I without distinguishing fiber varieties. The 1937 Marihuana Tax Act had similarly made no hemp exception, effectively ending American hemp cultivation that had peaked at 150,000 acres during World War II's "Hemp for Victory" campaign.

1998-2014: State Hemp Pilot Programs and the Farm Bill Exception

The 2014 Farm Bill created the first modern federal hemp exception, defining hemp as cannabis containing "not more than 0.3 percent delta-9 THC on a dry weight basis." Section 7606 authorized state agriculture departments and research institutions to operate hemp pilot programs, adopting Small's 1976 threshold into federal statute. The provision, championed by Senate Majority Leader Mitch McConnell of Kentucky, aimed to revive American hemp fiber and seed production without legalizing intoxicating cannabis. Between 2014 and 2018, 41 states established pilot programs enrolling 3,546 licensed growers cultivating 23,343 acres. Early participants focused on CBD extraction, as the 2014 law's research framework provided legal cover for cannabidiol production despite FDA's position that CBD remained an unapproved drug. The market remained small and legally ambiguous, with total U.S. hemp product sales estimated at $688 million in 2017.

2018: The Farm Bill's Hemp Legalization and Immediate Loopholes

The Agriculture Improvement Act of 2018 removed hemp from Schedule I of the Controlled Substances Act, legalizing cultivation, processing, and sale of cannabis containing ≤0.3% delta-9 THC. President Donald Trump signed the bill on December 20, 2018, with Section 10113 establishing hemp as an agricultural commodity under USDA jurisdiction. The law explicitly preserved FDA authority over hemp-derived products in food, drugs, and dietary supplements, creating a regulatory split that persists today. The 2018 Farm Bill's hemp definition—"the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis"—contained three critical ambiguities that entrepreneurs immediately exploited: First, the definition specified only delta-9 THC, not total THC or other THC isomers. This omission enabled the delta-8 THC market, where processors convert CBD from compliant hemp into delta-8 THC through chemical synthesis, producing intoxicating products technically derived from legal hemp. By 2024, delta-8 sales reached $8.4 billion annually. Second, the definition measured THC "on a dry weight basis" without specifying whether to include THCA, the non-intoxicating acid form that converts to delta-9 THC when heated. This created the THCA flower market, where cultivators sell high-THCA cannabis flower (15-25% THCA) that tests below 0.3% delta-9 THC in its raw state but becomes fully intoxicating when smoked or vaporized. THCA flower sales reached $6.2 billion in 2025. Third, the law contained no potency limits for finished hemp products, only for the source plant material. This enabled manufacturers to concentrate CBD or other cannabinoids into products containing hundreds of milligrams per serving, then add synthetic or semi-synthetic cannabinoids to create intoxicating effects.

2019-2021: USDA Rule Implementation and State Pushback

USDA published its interim final rule establishing the U.S. Domestic Hemp Production Program on October 31, 2019, requiring testing within 15 days of anticipated harvest using DEA-registered laboratories. The rule mandated that hemp exceeding 0.3% total THC (including THCA converted to delta-9 THC equivalent) must be destroyed, with "negligent violations" allowed for crops testing between 0.3% and 0.5% total THC. Growers exceeding 0.5% faced potential license suspension. The total THC testing requirement—measuring delta-9 THC plus 87.7% of THCA to account for decarboxylation—created immediate compliance problems. Hemp farmers in Colorado, Oregon, and Kentucky reported hot crop rates of 20-35% in 2020, particularly for outdoor cultivation where heat stress and late-season environmental factors can spike cannabinoid production. The National Hemp Association estimated $89 million in destroyed crops in 2020 alone. Twenty-three states requested USDA approval for state-run hemp programs using alternative testing protocols, including longer harvest windows and different THCA conversion factors. USDA approved 73 state and tribal plans by March 2022, though all were required to adopt the 0.3% total THC limit and 15-day testing window.

2022-2024: The Intoxicating Hemp Crisis and State Crackdowns

By 2023, intoxicating hemp products had penetrated 65,000+ retail locations including gas stations, vape shops, and online marketplaces, prompting 18 states to enact emergency restrictions. The proliferation of delta-8 THC, delta-10 THC, THC-O acetate, HHC (hexahydrocannabinol), and THCA flower created a parallel intoxicating cannabis market operating without the testing, labeling, or age verification requirements imposed on state-licensed marijuana programs. Colorado became the first state to restrict intoxicating hemp, with HB 1317 (2023) limiting delta-8 and other semi-synthetic cannabinoids to 0.3% in finished products. Oregon, Washington, and New York followed with similar restrictions in 2023-2024. However, enforcement proved difficult: a 2024 Oregon Liquor and Cannabis Commission sweep of Portland retailers found 67% of tested delta-8 products exceeded legal limits, with 23% containing unlabeled contaminants including heavy metals and residual solvents. The FDA issued warning letters to 22 companies marketing delta-8 products in 2023, citing violations of the Federal Food, Drug, and Cosmetic Act, but took no seizure actions. In congressional testimony on March 14, 2024, FDA Principal Deputy Commissioner Namandjé Bumpus stated the agency lacked sufficient resources and clear statutory authority to regulate the estimated 12,000 companies selling intoxicating hemp products.

2025-2026: Federal Reform Proposals and Industry Fragmentation

The Hemp and Hemp-Derived Products Regulation Act, introduced in the House on February 8, 2025, proposed raising the federal limit to 1.0% total THC and establishing FDA registration for hemp processors. The bill, sponsored by Representatives James Comer (R-KY) and Chellie Pingree (D-ME), gained 47 co-sponsors but stalled in committee amid opposition from the National Association of Cannabis Businesses, which argued the higher limit would legitimize intoxicating hemp while undercutting state-licensed marijuana markets. DEA Administrator Anne Milgram, in testimony before the Senate Judiciary Committee on September 12, 2025, stated that delta-8 THC and other semi-synthetic cannabinoids "may be considered controlled substance analogues" under 21 U.S.C. § 813, potentially subjecting manufacturers to federal prosecution. However, DEA has not pursued criminal cases, citing resource constraints and the ambiguous legal status of hemp-derived substances. The June 2026 commentary from the International Cannabis Business Conference, triggering renewed debate, argued that "any arbitrary THC limit will create compliance problems and market distortions" and advocated for a regulatory framework based on product potency and intended use rather than plant THC content. This position reflects growing consensus among agricultural economists and some hemp farmers that the current binary classification is scientifically and commercially unsustainable.

Key Players

U.S. Department of Agriculture (USDA)

USDA's Agricultural Marketing Service administers the U.S. Domestic Hemp Production Program, approving state and tribal plans and enforcing the 0.3% total THC limit for cultivation. The agency has approved 73 state and tribal hemp programs as of May 2026, covering approximately 84% of U.S. hemp acreage. USDA's 2021 final rule maintained the 0.3% total THC threshold and 15-day pre-harvest testing window despite receiving 4,630 public comments, 68% of which requested higher limits or longer testing windows. The agency stated it lacked statutory authority to modify the limit established by Congress in the 2018 Farm Bill.

Food and Drug Administration (FDA)

FDA maintains regulatory authority over hemp-derived products in food, dietary supplements, and drugs, but has issued no comprehensive regulations as of June 2026. The agency's position, articulated in a January 2023 report to Congress, is that CBD and other cannabinoids cannot be legally added to food or marketed as dietary supplements because they were investigated as drugs before being marketed in food. However, FDA has exercised enforcement discretion, issuing warning letters for egregious violations but not pursuing systematic market removal. The regulatory vacuum has enabled the intoxicating hemp market to flourish outside FDA oversight.

Drug Enforcement Administration (DEA)

DEA retains authority over controlled substances and has issued conflicting guidance on hemp-derived cannabinoids. An August 2020 interim final rule stated that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances," which DEA later clarified could include delta-8 THC produced through chemical conversion of CBD. However, the agency has not classified delta-8 or other hemp-derived cannabinoids as controlled substances through formal rulemaking, creating legal uncertainty. DEA's laboratory registration program requires hemp testing facilities to obtain registration, adding $3,047 in annual costs per laboratory.

National Hemp Association

The National Hemp Association, representing 3,200 hemp farmers and processors, advocates for raising the federal limit to 1.0% total THC and extending pre-harvest testing windows to 30 days. The organization's 2025 policy platform argues that the current limit "criminalizes farmers for environmental factors beyond their control" and that European Union standards allowing up to 0.3% delta-9 THC (not including THCA) provide a more workable model. The association has opposed state restrictions on intoxicating hemp products, arguing they threaten market access for compliant hemp farmers.

U.S. Hemp Roundtable

The U.S. Hemp Roundtable, a coalition of 200+ hemp companies including major CBD brands, has taken a more nuanced position, supporting federal regulation of intoxicating hemp products while maintaining the 0.3% cultivation limit. In a March 2026 policy statement, the organization endorsed FDA registration requirements for hemp processors and potency limits for delta-8 and similar products, arguing that "the intoxicating hemp market threatens the viability of the legitimate CBD industry by inviting federal crackdown."

National Association of Cannabis Businesses (NACB)

NACB, representing state-licensed marijuana operators, has lobbied aggressively for restricting intoxicating hemp, arguing it creates an unlicensed marijuana market that undercuts regulated businesses. The organization supported Colorado's HB 1317 and similar state restrictions, and has advocated for federal legislation limiting hemp-derived cannabinoids to 0.3% in finished products. NACB's position has created tension with hemp industry groups, with some observers noting the irony of marijuana businesses seeking stricter cannabis regulation.

State Agriculture Departments

State agriculture departments in Kentucky, North Carolina, Tennessee, Montana, and Oregon have emerged as key voices advocating for federal flexibility. Kentucky Agriculture Commissioner Jonathan Shell, in testimony before the House Agriculture Committee on April 18, 2025, requested authority to adopt a 0.5% total THC tolerance for outdoor cultivation, noting that Kentucky's climate makes the 0.3% limit "nearly impossible to meet consistently for fiber and grain varieties." North Carolina adopted a 1.0% total THC limit for its state-run program in 2024, though this requires USDA approval and remains pending.

Legal and Regulatory Framework

Federal Statutes

The Agriculture Improvement Act of 2018, Public Law 115-334, Section 10113, defines hemp as cannabis containing "not more than 0.3 percent delta-9 tetrahydrocannabinol concentration... on a dry weight basis." This definition appears in 7 U.S.C. § 1639o and removes hemp from Schedule I of the Controlled Substances Act, 21 U.S.C. § 812. However, the Controlled Substances Act's definition of "marihuana" in 21 U.S.C. § 802(16) was amended to exclude hemp, creating the binary classification: cannabis ≤0.3% delta-9 THC is hemp (legal), cannabis >0.3% is marijuana (Schedule I). The 2018 Farm Bill preserved FDA authority under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., over hemp-derived products. Section 10114 explicitly states that nothing in the hemp provisions affects FDA's authority to regulate products containing cannabis or cannabis-derived compounds. This split jurisdiction—USDA for cultivation, FDA for products—has created regulatory gaps exploited by the intoxicating hemp market.

USDA Regulations

The U.S. Domestic Hemp Production Program, codified at 7 CFR Part 990, establishes testing, sampling, and disposal requirements for hemp cultivation. Key provisions include: - Hemp must be tested within 15 days of anticipated harvest using DEA-registered laboratories - Testing must measure total THC, calculated as delta-9 THC plus (THCA × 0.877) - Hemp exceeding 0.3% total THC must be destroyed by plowing under, composting, or burning - Crops testing 0.3-0.5% total THC constitute "negligent violations" if unintentional - Crops exceeding 0.5% total THC may result in license suspension - States and tribes may submit plans for USDA approval to administer their own programs The 0.877 conversion factor represents the molecular weight ratio of THC to THCA, accounting for the loss of a carboxyl group during decarboxylation. This "total THC" measurement is more stringent than measuring only delta-9 THC, as THCA typically constitutes 90-95% of total THC in raw plant material.

State Variations

Twenty-three states have enacted hemp THC limits or intoxicating hemp restrictions that differ from federal standards, creating a complex compliance landscape. State approaches fall into three categories: **States maintaining 0.3% delta-9 THC (federal standard):** Alabama, Alaska, Arkansas, Georgia, Idaho, Indiana, Iowa, Kansas, Louisiana, Mississippi, Nebraska, South Carolina, South Dakota, Texas, Wisconsin. These states generally prohibit delta-8 and other intoxicating hemp products through separate statutes or emergency rules. **States adopting higher cultivation limits:** North Carolina (1.0% total THC, pending USDA approval), Hawaii (0.5% total THC for state-licensed growers), Montana (0.3% delta-9 THC, not including THCA). These states argue higher limits reduce crop destruction while maintaining distinction from marijuana. **States restricting intoxicating hemp products:** Colorado (0.3% total THC in finished products), Oregon (0.5 mg delta-8 per serving), Washington (0.3% total THC in finished products), New York (0.3% delta-9 THC in finished products), California (0.3% total THC in finished products), Vermont (0.3% total THC in finished products). These states allow hemp cultivation under federal standards but restrict intoxicating cannabinoids in consumer products. The patchwork creates interstate commerce challenges. A hemp product legal in Tennessee (which allows THCA flower) becomes illegal when transported to Colorado (which prohibits it). Online retailers face compliance with destination-state laws, though enforcement remains limited.

Pending Litigation

AK Futures LLC v. Boyd Street Distro LLC, pending in the U.S. District Court for the Central District of California, challenges DEA's authority to classify delta-8 THC as a controlled substance. The plaintiff, a hemp processor, argues that delta-8 derived from legal hemp through isomerization is itself legal hemp under the 2018 Farm Bill's definition of "all derivatives, extracts, cannabinoids, isomers" of hemp. The case, filed March 2025, could determine whether semi-synthetic cannabinoids derived from compliant hemp retain legal status. As of June 2026, the court has not ruled on DEA's motion to dismiss.

Market and Business Implications

The $28 Billion Intoxicating Hemp Market

Intoxicating hemp products generated $28.3 billion in sales in 2025, according to Whitney Economics, exceeding legal marijuana sales in 18 states. The market comprises: - Delta-8 THC products: $8.4 billion (vapes, edibles, tinctures) - THCA flower: $6.2 billion (smokable flower, pre-rolls) - Delta-10 THC products: $2.1 billion - HHC products: $1.8 billion - THC-O and other novel cannabinoids: $1.4 billion - CBD products (non-intoxicating): $8.4 billion The intoxicating segment grew 340% from 2022 to 2025, driven by availability in states without adult-use marijuana programs and lower prices compared to licensed marijuana (delta-8 vapes average $18-25 vs. $35-50 for licensed marijuana vapes). Distribution through convenience stores, gas stations, and online marketplaces—channels unavailable to licensed marijuana—provided market access advantages.

Impact on Licensed Cannabis Operators

Multi-state operators reported $4.2 billion in estimated lost revenue to intoxicating hemp in 2025, with the greatest impact in limited-license states. Curaleaf, Trulieve, and Green Thumb Industries cited hemp competition in earnings calls, with Curaleaf CEO Matt Darin stating in a February 2026 investor presentation that "unregulated hemp products are the single greatest threat to state-licensed markets, greater than federal prohibition itself." The competitive disadvantage stems from regulatory arbitrage: - **Testing requirements:** Licensed marijuana undergoes potency, pesticide, heavy metal, microbial, and residual solvent testing costing $400-800 per batch. Hemp products face no mandatory testing in most states. - **Tax burden:** Licensed marijuana carries 15-37% excise taxes plus sales tax. Hemp products pay only sales tax. - **Licensing costs:** Marijuana licenses cost $75,000-500,000 initially plus $50,000-200,000 annually. Hemp processing requires no license in most states. - **Purchase limits:** Marijuana sales are limited to 1-2 ounces per transaction. Hemp has no purchase limits. - **Distribution channels:** Marijuana is restricted to licensed dispensaries. Hemp is sold in 65,000+ retail locations. Some MSOs have entered the hemp market through subsidiaries. Curaleaf launched a hemp-derived delta-8 line in 2024, and Ayr Wellness acquired hemp processor Herban Industries in March 2025 for $47 million. However, most large operators have avoided hemp due to reputational risk and uncertainty about federal enforcement.

Hemp Farmer Economics

The 0.3% limit creates binary economic outcomes for hemp farmers: full revenue realization or total crop loss. A 2025 Cornell University study of 340 hemp farms found: - Average revenue per acre for compliant hemp: $12,400 (CBD biomass), $18,200 (THCA flower) - Average loss per acre for hot crops: $8,200 (including seed, inputs, labor, testing) - Percentage of outdoor farms experiencing hot crops (2023-2024): 22% - Percentage of greenhouse farms experiencing hot crops: 7% The economic risk has driven consolidation toward greenhouse cultivation and genetics companies offering "guaranteed compliant" cultivars. Indoor and greenhouse acreage increased 67% from 2022 to 2025, while outdoor acreage declined 31%. However, greenhouse production costs are 3-4 times higher than outdoor, reducing profitability. Some farmers have shifted to THCA flower cultivation, growing high-THCA genetics that test below 0.3% delta-9 THC but produce intoxicating effects when consumed. This strategy exploits the testing loophole but carries legal risk if states or federal agencies reclassify THCA flower as marijuana. Kentucky banned THCA flower sales in May 2024, stranding farmers with $23 million in unsold inventory according to Kentucky Hemp Association estimates.

Investment and Capital Markets

Venture capital investment in hemp companies totaled $1.2 billion in 2025, down 43% from 2023's $2.1 billion peak, reflecting regulatory uncertainty. Investors cite three primary concerns: potential FDA crackdown on intoxicating hemp, state-level restrictions fragmenting markets, and reputational risk from association with unregulated products. Several institutional investors, including pension funds and university endowments, have adopted policies prohibiting hemp investments pending federal regulatory clarity. Public markets have been more receptive. Charlotte's Web, the largest CBD brand, trades on the Toronto Stock Exchange with a $420 million market capitalization as of June 2026. The company has avoided intoxicating hemp products, focusing on CBD wellness products and advocating for FDA regulation. In contrast, several delta-8 companies that pursued SPAC mergers in 2023-2024 have seen valuations collapse 70-85% amid regulatory uncertainty.

What Experts Say

Dr. Jonathan Page, an adjunct professor at the University of British Columbia and co-founder of Anandia Laboratories, has stated that the 0.3% limit "has no scientific basis for distinguishing intoxicating from non-intoxicating cannabis." In a 2024 article in the Journal of Cannabis Research, Page and co-authors noted that intoxication depends on consumption method, dose, and individual tolerance, not plant THC content. A person smoking 1 gram of 0.3% THC hemp flower would consume 3 mg THC, potentially producing mild intoxication in a naive user, while a person consuming 0.1 gram of 20% THC marijuana would consume 20 mg, producing strong intoxication. The authors argued for regulation based on product potency and labeling rather than plant classification. Dr. Mahmoud ElSohly, director of the University of Mississippi's Marijuana Project and a leading cannabis researcher, has advocated for a 1.0% total THC limit for hemp cultivation. In testimony before the USDA in 2020, ElSohly noted that European Union standards allow up to 0.3% delta-9 THC (not including THCA), effectively permitting higher total THC than U.S. standards. ElSohly stated that a 1.0% total THC limit would "reduce crop destruction by approximately 60% while maintaining a clear distinction from marijuana cultivars, which typically contain 10-25% total THC." Shane Pennington, counsel at Vicente LLP and a leading hemp industry attorney, has argued that the 2018 Farm Bill's definition of hemp as including "all derivatives, extracts, cannabinoids, isomers" legally protects delta-8 and other hemp-derived cannabinoids. In a widely cited 2021 legal memorandum, Pennington wrote that "Congress explicitly legalized hemp derivatives and isomers without exception, and DEA lacks authority to re-schedule them without formal rulemaking." This interpretation has been contested by DEA and some legal scholars, who argue that semi-synthetic cannabinoids may constitute controlled substance analogues under 21 U.S.C. § 813. Dr. Peter Grinspoon, a primary care physician at Massachusetts General Hospital and cannabis policy expert, has expressed concern about intoxicating hemp products sold without age verification or dosing guidance. In a 2025 Harvard Health Blog post, Grinspoon noted that "delta-8 products marketed as 'legal' and 'natural' may mislead consumers about potency and safety, particularly when sold in gas stations alongside energy drinks." Grinspoon advocated for FDA regulation requiring child-resistant packaging, potency labeling, and age verification for all intoxicating cannabinoid products regardless of source. According to the National Conference of State Legislatures, 23 states enacted hemp-related legislation in 2024-2025, reflecting "widespread recognition that the federal framework is inadequate." NCSL's cannabis policy specialist, Alison Barkoff, stated in a May 2026 webinar that states are "filling the federal void" through varied approaches, but that the resulting patchwork "creates compliance burdens for businesses and confusion for consumers." Barkoff noted that comprehensive federal legislation addressing both cultivation limits and product regulation is "urgently needed but politically challenging given the competing interests of hemp farmers, marijuana operators, and public health advocates."

State-by-State Breakdown

California

California prohibits intoxicating hemp products under AB 45 (2023), which limits hemp-derived cannabinoids to 0.3% total THC in finished products. The law, effective January 1, 2024, requires hemp products to undergo testing equivalent to licensed marijuana and prohibits sales to persons under 21. Enforcement is split between the Department of Cannabis Control (for intoxicating products) and the Department of Public Health (for CBD products). As of May 2026, DCC has issued 127 cease-and-desist letters to retailers selling non-compliant delta-8 products, but no criminal prosecutions have occurred. Hemp cultivation remains legal under federal standards, with 412 registered growers cultivating 3,847 acres in 2025.

Colorado

Colorado enacted the nation's strictest intoxicating hemp restrictions through HB 1317 (2023), limiting delta-8 and other semi-synthetic cannabinoids to 0.3% in finished products and requiring Marijuana Enforcement Division registration for processors. The law defines "industrial hemp products" as those containing ≤0.3% total THC and "marijuana products" as those exceeding that limit, regardless of source. Retailers selling intoxicating hemp must obtain marijuana licenses, effectively ending gas station and convenience store sales. The Colorado Department of Revenue reported that delta-8 product availability declined 89% in the six months following implementation. Hemp farmers may cultivate under federal standards, with 1,247 registered operations in 2025.

Florida

Florida allows hemp cultivation and intoxicating hemp sales under federal standards, with no state-level restrictions on delta-8, THCA flower, or other products. The state's hemp program, administered by the Department of Agriculture and Consumer Services, has approved 1,893 licensed growers cultivating 18,432 acres as of April 2026, the second-largest hemp acreage nationally. The absence of restrictions has made Florida a hub for intoxicating hemp manufacturing and distribution. However, legislation to restrict delta-8 (SB 1676) was introduced in the 2026 legislative session and remains pending in committee as of June 2026.

Kentucky

Kentucky, the birthplace of federal hemp legalization, prohibits THCA flower sales under an emergency regulation issued by the Department of Agriculture in May 2024. The regulation defines marijuana to include "any cannabis flower or product intended for smoking or vaporization containing more than 0.3% total THC, including THCA," effectively banning high-THCA flower despite its compliance with federal testing standards. The rule has been challenged in Franklin Circuit Court by the Kentucky Hemp Association, which argues the Department exceeded its statutory authority. Hemp cultivation remains robust, with 2,147 licensed growers on 24,680 acres in 2025, the largest hemp acreage nationally. Delta-8 and other non-flower products remain legal.

Michigan

Michigan allows intoxicating hemp sales without state-level restrictions, creating competition with the state's licensed marijuana market. The Michigan Marijuana Regulatory Agency has no jurisdiction over hemp products, and the Department of Agriculture and Rural Development has not enacted intoxicating hemp rules. Licensed marijuana retailers have lobbied for restrictions, citing 15-25% revenue declines in markets with high hemp product availability. Legislation to regulate intoxicating hemp (HB 5080) was introduced in March 2026 but has not advanced. Hemp cultivation is permitted under federal standards, with 687 registered growers in 2025.

New York

New York restricts intoxicating hemp under regulations issued by the Office of Cannabis Management in September 2023, limiting hemp-derived cannabinoids to 0.3% delta-